NEW YORK (GenomeWeb) — Cancer diagnostics developer Precipio said today that it will implement a 1-for-15 reverse stock split in a bid to regain compliance with a Nasdaq listing requirements.
In a filing with the US Securities and Exchange Commission, New Haven, Connecticut-based firm said that it received notice late last month that it did not meet the exchange's $1 minimum bid price requirement and that its stock was facing delisting.